ZEALAND PHARMA
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (โZealandโ) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealandโs first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is ... marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealandโs business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
ZEALAND PHARMA
Industry:
Biopharma Biotechnology Health Care
Founded:
1998-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.zealandpharma.com
Total Employee:
101+
Status:
Active
Contact:
45 88 77 36 00
Email Addresses:
[email protected]
Total Funding:
271.52 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Font Awesome Domain Not Resolving
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with superior immune cell therapies.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2020-02-10 | Valeritas | Valeritas acquired by Zealand Pharma | 23 M USD |
2019-10-23 | Encycle Therapeutics | Encycle Therapeutics acquired by Zealand Pharma | N/A |
Investors List
Oberland Capital
Oberland Capital investment in Post-IPO Debt - Zealand Pharma
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Equity - Zealand Pharma
Idinvest Partners
Idinvest Partners investment in Venture Round - Zealand Pharma
Innovation Capital
Innovation Capital investment in Venture Round - Zealand Pharma
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2019-01-08 | Beta Bionics | Zealand Pharma investment in Series B - Beta Bionics | 63 M USD |
Key Employee Changes
Official Site Inspections
http://www.zealandpharma.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.44 K
- Host name: 104.47.160.14
- IP address: 104.47.160.14
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091